Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma

This is a phase 3, multicentre, randomised controlled trial to study the effectiveness and toxicity of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy alone in treating patients with locoregionally recurrent nasopharyngeal carcinoma.

Trial Details

NCT ID
NCT04376866
Phase
PHASE3
Sponsor
Cancer Hospital of Guangxi Medical University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Toripalimab
Locations (sample)
  • Nanning, Guangxi, China|22.81667,108.31667

Key Eligibility Criteria

  • Patients with newly histologically confirmed recurrent nasopharyngeal carcinoma, or Two or more image examinations (MRI, and PET-CT) show the recur…
  • staged as rT3-4N0-1M0或rT1-4N2-3M0 （according to the 8th AJCC edition）
  • Satisfactory performance status: ECOG (Eastern Cooperative OncologyGroup) scale 0-1
  • Neutrophil ≥ 1.5×109 /L and PLT ≥4×109 /L and HGB ≥90 g/L

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →